Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer

Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer

The CDK4/6 inhibitor, abemaciclib, is now the standard of care adjuvant therapy for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) tumors at high risk of recurrence. Real-world usage uncovers emerging side effects that may have been previousl...

Full description

Bibliographic Details
Main Authors: Neil Carleton, Julia Foldi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Medicine
Subjects:
ER+ breast cancer
Abemaciclib
hyponatremia
SIADH
early-stage breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1338566/full

Similar Items

Similar Items